false
English
Catalog
2022 World Conference on Lung Cancer (ePosters)
EP08.02-136. Final Analysis of a Phase II Study: A ...
EP08.02-136. Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Back to course
Pdf Summary
This study evaluated the efficacy and safety of combining the anti-angiogenic agent anlotinib with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who had previously failed platinum-based chemotherapy. The study, which enrolled 48 patients, showed that anlotinib plus docetaxel demonstrated a high objective response rate (ORR) and improved progression-free survival (PFS) and overall survival (OS) compared to historical results of docetaxel alone. The combination therapy also showed tolerable adverse events (AEs). Notably, patients who experienced hand-foot skin reactions (HFSR) due to anlotinib had longer survival. The final analysis of the study confirmed these findings.<br /><br />The single-arm phase study included patients with stage IIIB or IV NSCLC who had previously failed platinum-based doublet chemotherapy and had an ECOG performance status of 0-1. The administration consisted of oral anlotinib (12 mg per day taken for 14 days) and intravenous docetaxel (60 mg/m2 on Day 1 of each 21-day cycle). The primary endpoint was ORR, and secondary endpoints included disease control rate (DCR), PFS, OS, and safety.<br /><br />Results showed an ORR of 35.6%, with a DCR of 84.4%. The median duration of response was 5.7 months, and the median PFS was 5.3 months. The median OS was 13.8 months. Subgroup analysis revealed that patients with HFSR had longer OS compared to those without HFSR. Adverse events were mostly grade 1-2, with no grade 4 events observed.<br /><br />In conclusion, the combination of anlotinib and docetaxel showed promising efficacy and manageable safety in advanced NSCLC patients who had failed platinum-based chemotherapy. The results support the use of this combination as a potential treatment option for these patients. Further research is needed to validate and expand upon these findings.
Asset Subtitle
Juan Shen
Meta Tag
Speaker
Juan Shen
Topic
Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
Keywords
anlotinib
docetaxel
non-small cell lung cancer
NSCLC
platinum-based chemotherapy
objective response rate
progression-free survival
overall survival
adverse events
treatment option
×
Please select your language
1
English
5
普通话
11
Dutch